ClinicalTrials.gg
CompletedNCT02160782ICONICUpdated Jul 14, 2021Results posted

Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)

A Phase 2 interventional study of LUM001 (Maralixibat) and Placebo in Alagille Syndrome, sponsored by Mirum Pharmaceuticals, Inc.. Completed at 9 sites in 6 countries. Open to participants aged 12 Months to 18 Years. Per ClinicalTrials.gov, last updated 2021-07-14.

Sponsored by Mirum Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
31
Allocation
Randomized
Ages
12 Months to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc. — 2 open to participants now, 2 under way, none of them phase 3. Alagille Syndrome · Mirum Pharmaceuticals, Inc..

Started
2014
with 2 others
Phase 2
6 of 10
none open now
Registered
6th of 10
by date

Among the 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc., this one is one of 3 that started in 2014, is one of 6 in phase 2, and was the 6th registered.

Alagille Syndrome

31 studies on the registry are indexed under Alagille Syndrome; 11 are open to participants now.

Browse Alagille Syndrome studies →

Open to participants now

2 of the 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc. are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 10 Alagille Syndrome studies recruiting now, 7 (70%) set no upper age limit and 3 (30%) stop at 75 or younger; 9 take children under 18; none take healthy volunteers.

This study: 12 Months to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc., or all of them as a file.
02

Study summary

This is a long-term, open-label study with a double-blind, placebo-controlled, randomized drug withdrawal period in children with Alagille Syndrome (ALGS) designed to evaluate the safety and efficacy of LUM001 (Also known as maralixibat or MRX).

Read the detailed description

The study is divided into 6 parts: a 6-week open-label, dose escalation period, a 12-week open-label stable dosing period, a 4-week randomized, double-blind, placebo-controlled drug withdrawal period, a 26-week long-term stable dosing period, and an a 52-week optional follow-up treatment period, and a long-term optional follow-up treatment period for eligible participants who choose to stay on treatment with LUM001.

03

Conditions studied

  • Alagille Syndrome

Browse trials for

04

Who can participate

Ages eligible
12 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between the ages of 12 months and 18 years inclusive.
  • Diagnosis of ALGS.
  • Evidence of cholestasis (one or more of the following):

    1. Total serum bile acid > 3x for age.
    2. Conjugated > 1 mg/dL.
    3. Fat soluble vitamin deficiency otherwise unexplainable.
    4. GGT > 3x ULN for age.
    5. Intractable pruritus explainable only by liver disease.
  • Females of must have a negative serum pregnancy test during Screening.
  • Males and females of child-bearing potential who are sexually active, or are not currently sexually active during the study, but become sexually active during the period of the study and 30 days following the last dose of study drug, must agree and use acceptable during the trial.
  • Participant is expected to have a consistent caregiver(s) for the duration of the study.
  • and assent (per IRB/IEC) as appropriate.
  • Access to phone for scheduled calls from study site.
  • Caregivers (and age-appropriate participants) must be willing and able to use an eDiary device during the study.
  • Caregivers (and age-appropriate participants) must digitally accept the licensing agreement in the eDiary software.
  • Caregivers (and age-appropriate participants) must complete at least 10 eDiary reports (morning or evening) during each of two consecutive weeks of the screening period (maximum possible reports = 14 per week).
  • Average daily score >2 on the Itch Reported Outcome (ItchRO™) questionnaire (maximum possible daily score of 4) for two consecutive weeks in the screening period, prior to dosing. A daily score is the higher of the scores for the morning and evening ItchRO. The average daily score is the sum of all daily scores divided by the number of days the ItchRO was completed.

Inclusion Criteria for participants to be eligible for the 52-week optional follow-up treatment period:

  • Completed the protocol through the Week 48 visit with no safety concerns. Participants who were discontinued due to safety reasons can be rechallenged if blood tests are back to relatively normal values for this patient population and participant does not meet any of the protocol's stopping rules. The decision will be made by the investigator in consultation with the sponsor medical monitor.
  • Participants who have undergone a surgical disruption of the enterohepatic circulation will not be eligible to enter into the follow up treatment period.
  • Participants who were discontinued for other reasons will be considered for the 52-week optional follow-up treatment period on an individual basis. The decision will be made by the investigator in consultation with the sponsor medical monitor.

Inclusion Criteria for participants with LUM001dosing interruption \<7 days, or >=7 days:

  • The Participant has either: completed the protocol through the Week 48 visit with no major safety concerns OR discontinued due to safety reasons judged unrelated to the study drug, and laboratory results have returned to levels acceptable for this patient population or individual and participant does not meet any of the protocol's stopping rules at the time of entry into the follow-up period. The decision will be made by the investigator in consultation with the sponsor medical monitor. [Participants who were discontinued for other reasons will be considered on an individual basis.]
  • Females of childbearing potential must have a negative urine or serum pregnancy test (beta- human chorionic gonadotropin [β-hCG]) at the time of entry into the long-term optional follow-up treatment period.
  • Males and females of child-bearing potential who are sexually active, or are not currently sexually active during the study, but become sexually active during the period of the study and 30 days following the last dose of study drug, must agree and use acceptable contraception during the trial.
  • Informed consent and assent (per IRB/EC) as appropriate.
  • Access to phone for scheduled calls from study site.
  • Caregivers (and age-appropriate participants) must be willing and able to use an eDiary device during the study.

Exclusion criteria

Exclusion Criteria:

  • Chronic diarrhea requiring ongoing intravenous fluid or nutritional intervention.
  • Surgical interruption of the enterohepatic circulation.
  • Previous liver transplant
  • Decompensated cirrhosis ( >15 x , >1.5 [unresponsive to vitamin K therapy], albumin \<3.0 g/dL, history or presence of ascites, variceal hemorrhage, and/or encephalopathy).
  • History or presence of other concomitant liver disease.
  • History or presence of any other disease or condition known to interfere with the absorption, distribution, metabolism or excretion of drugs, including bile salt metabolism in the intestine (eg, inflammatory bowel disease).
  • History or presence of gallstones or kidney stones.
  • Known diagnosis of (HIV) infection.
  • Cancers, except for in situ carcinoma, or cancers treated at least 5 years prior to Screening with no evidence of recurrence.
  • Recent medical history or current status that suggests that the participant may be unable to complete the study.
  • Any female who is pregnant or lactating or who is planning to become pregnant during the study period.
  • Known history of alcohol or substance abuse.
  • Administration of bile acid or lipid binding resins within 28 days prior to screening and throughout the trial.
  • Known to LUM001 or any of its components.
  • Receipt of drug, biologic, or medical device within 28 days prior to screening, or 5 half-lives of the study agent, whichever is longer.
  • History of non-adherence to medical regimens, unreliability, mental instability or incompetence that could compromise the validity of or lead to nonadherence with the study protocol based upon investigator judgment.
  • Any other conditions or abnormalities which, in the opinion of the investigator or sponsor medical monitor, may compromise the safety of the participant, or interfere with the participant participating in or completing the study.
  • Participants weighing over 50 kg at screening.

Exclusion Criteria for participants with LUM001 dosing interruption >=7 days:

  • All exclusion criteria mentioned above apply upon entry into the long-term optional follow-up period, with the exception of participants weighing over 50 kg at screening.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
31 participants (actual)

Study arms

  • Experimental
    LUM001 (Maralixibat)

    LUM001, also known as Maralixibat (MRX) will be administered orally once a day (QD) up to 400 microgram per kilogram per day (mcg/kg/day) up to Week 52, followed by an increase in dose orally twice a day (BID) during long-term follow-up based on efficacy (serum bile acid \[sBA\] level and ItchRO\[Obs\] score) and safety assessment. Note: 400 mcg/kg maralixibat chloride is equivalent to 380 mcg/kg free maralixibat.

    Drug: LUM001 (Maralixibat)

  • Placebo comparator
    Placebo

    Placebo will be administered orally once a day during randomized withdrawal period (Week 19 to Week 22)

    Drug: Placebo

Interventions

  • LUM001, also known as Maralixibat (MRX) will be administered orally Once Daily (OD). To be administered Twice Daily (BID) for patients who are eligible.

  • DrugPlacebo

    Placebo will be administered orally once daily during randomized withdrawal period

06

What researchers measure

Primary outcomes

  1. Change From Week 18 to Week 22 in Fasting sBA Levels in Participants Who Had a Reduction in sBA ≥50% From Baseline to Week 12 or Week 18

    The primary efficacy endpoint of this study was the mean change from Week 18 to Week 22 (the RWD period) of fasting sBA levels in participants who had a reduction in sBA ≥50% from baseline to Week 12 or Week 18 (Modified Intent-to-Treat \[MITT\] Population). Five participants in the MRX group and 10 participants in the placebo group met the prespecified sBA reduction criteria.

    Time frame: Week 18 to Week 22

Secondary outcomes

  1. Change From Baseline to Week 18 in Fasting sBA Levels

    This secondary efficacy endpoint is the mean change from baseline to Week 18 in fasting sBA levels

    Time frame: Baseline to Week 18

  2. Change From Baseline to Week 18 in Pruritus as Measured by ItchRO (Obs)

    This secondary efficacy endpoint is the change from baseline to Week 18 in pruritus as measured by ItchRO(Obs) weekly average morning score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe).

    Time frame: Baseline to Week 18

  3. Change From Baseline to Week 18 in Pruritus as Measured by ItchRO (Pt)

    This secondary efficacy endpoint is the change from baseline to Week 18 in pruritus as measured by ItchRO(Pt) weekly average morning score

    Time frame: Baseline to Week 18

  4. Change From Week 18 to Week 22 in Pruritus as Measured by ItchRO(Obs)

    This secondary efficacy endpoint is the change from Week 18 to Week 22 in pruritus as measured by ItchRO(Obs) weekly average morning score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe).

    Time frame: Week 18 to Week 22

  5. Change From Week 18 to Week 22 in Pruritus as Measured by ItchRO(Pt)

    This secondary efficacy endpoint is the change from Week 18 to Week 22 in pruritus as measured by ItchRO(Pt) weekly average morning score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe).

    Time frame: Week 18 to Week 22

  6. Change From Baseline to Week 18 in Alkaline Phosphatase

    This secondary efficacy endpoint is the mean change from baseline to Week 18 in ALP

    Time frame: Baseline to Week 18

  7. Change From Week 18 to Week 22 in Alkaline Phosphatase

    This secondary efficacy endpoint is the mean change from Week 18 to Week 22 in ALP

    Time frame: Week 18 to Week 22

  8. Change From Baseline to Week 18 in Alanine Aminotransferase

    This secondary efficacy endpoint is the mean change from baseline to Week 18 in ALT

    Time frame: Baseline to Week 18

  9. Change From Week 18 to Week 22 in Alanine Aminotransferase

    This secondary efficacy endpoint is the mean change from Week 18 to Week 22 in alanine aminotransferase (ALT)

    Time frame: Week 18 to Week 22

  10. Change From Baseline to Week 18 in Total Bilirubin

    This secondary efficacy endpoint is the mean change from baseline to Week 18 in total bilirubin

    Time frame: Baseline to Week 18

  11. Change From Week 18 to Week 22 in Total Bilirubin

    This secondary efficacy endpoint is the mean change from Week 18 to Week 22 in total bilirubin

    Time frame: Week 18 to Week 22

  12. Change From Baseline to Week 18 in Direct Bilirubin

    This secondary efficacy endpoint is the mean change from baseline to Week 18 in direct bilirubin

    Time frame: Baseline to Week 18

  13. Change From Week 18 to Week 22 in Direct Bilirubin

    This secondary efficacy endpoint is the mean change from Week 18 to Week 22 in direct bilirubin

    Time frame: Week 18 to Week 22

07

Results

Posted Jul 14, 2021
Limitations and caveats
Limitations of the trial such as small numbers of subjects analyzed or technical problems leading to unreliable data.

Participant flow

The participants were enrolled at 9 sites in 6 countries (Australia, UK, France, Poland, Spain and Belgium) between 28 October 2014 and 11 September 2015

Open-label Period: Maralixibat
Participant flow — Open-label Period: Maralixibat
MilestoneOpen-label Period: Maralixibat (LUM001)Randomized Withdrawal Period: MRXRandomized Withdrawal Period: PlaceboAfter Randomized Withdrawal Period: MaralixibatLong-term Extension Period: Maralixibat
Started310000
Completed290000
Not completed20000
Withdrew: Adverse event20000
Randomized Withdrawal Period- Pbo vs MRX
Participant flow — Randomized Withdrawal Period- Pbo vs MRX
MilestoneOpen-label Period: Maralixibat (LUM001)Randomized Withdrawal Period: MRXRandomized Withdrawal Period: PlaceboAfter Randomized Withdrawal Period: MaralixibatLong-term Extension Period: Maralixibat
Started0131600
Completed0131600
Not completed00000
After Randomized Withdrawal: Maralixibat
Participant flow — After Randomized Withdrawal: Maralixibat
MilestoneOpen-label Period: Maralixibat (LUM001)Randomized Withdrawal Period: MRXRandomized Withdrawal Period: PlaceboAfter Randomized Withdrawal Period: MaralixibatLong-term Extension Period: Maralixibat
Started000290
Completed000230
Not completed00060
Withdrew: Adverse event00010
Withdrew: Did not consent to protocol amendment for long term extension00050
Long-term Extension Period: Maralixibat
Participant flow — Long-term Extension Period: Maralixibat
MilestoneOpen-label Period: Maralixibat (LUM001)Randomized Withdrawal Period: MRXRandomized Withdrawal Period: PlaceboAfter Randomized Withdrawal Period: MaralixibatLong-term Extension Period: Maralixibat
Started000023
Completed000014
Not completed00009
Withdrew: Did not consent to protocol amendment00004
Withdrew: Physician decision00001
Withdrew: Adverse event00003
Withdrew: Withdrawal by caregiver00001

Outcome measures

PrimaryChange From Week 18 to Week 22 in Fasting sBA Levels in Participants Who Had a Reduction in sBA ≥50% From Baseline to Week 12 or Week 18

The primary efficacy endpoint of this study was the mean change from Week 18 to Week 22 (the RWD period) of fasting sBA levels in participants who had a reduction in sBA ≥50% from baseline to Week 12 or Week 18 (Modified Intent-to-Treat \[MITT\] Population). Five participants in the MRX group and 10 participants in the placebo group met the prespecified sBA reduction criteria.

Time frame:
Week 18 to Week 22
Reported as:
Least squares mean · μmol/L
Change From Week 18 to Week 22 in Fasting sBA Levels in Participants Who Had a Reduction in sBA ≥50% From Baseline to Week 12 or Week 18
μmol/LRandomized Withdrawal Period: MRXRandomized Withdrawal Period: Placebo
Change From Week 18 to Week 22 in Fasting sBA Levels in Participants Who Had a Reduction in sBA ≥50% From Baseline to Week 12 or Week 18-21.73 ± 43.12595.55 ± 30.488
Statistical analysis
  • Randomized Withdrawal Period: MRX vs Randomized Withdrawal Period: Placebo · ANCOVA · p = 0.0464 · Mean difference (net): -117.28 · 95% CI -232.38 to -2.18
SecondaryChange From Baseline to Week 18 in Fasting sBA Levels

This secondary efficacy endpoint is the mean change from baseline to Week 18 in fasting sBA levels

Time frame:
Baseline to Week 18
Reported as:
Mean · μmol/L
Change From Baseline to Week 18 in Fasting sBA Levels
μmol/LOpen-label Period: MRX BaselineOpen-label Period: MRX Week 18
Change From Baseline to Week 18 in Fasting sBA Levels283.43 ± 210.569192.50 ± 161.278
Statistical analysis
  • Open-label Period: MRX Baseline vs Open-label Period: MRX Week 18 · Student's t-test · p = 0.0005 (Data for this analysis were obtained from 31 participants at baseline; 29 of those participants contributed Week 18 data.) · Mean difference (net): -87.73 · 95% CI -133.37 to -42.09
SecondaryChange From Baseline to Week 18 in Pruritus as Measured by ItchRO (Obs)

This secondary efficacy endpoint is the change from baseline to Week 18 in pruritus as measured by ItchRO(Obs) weekly average morning score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe).

Time frame:
Baseline to Week 18
Reported as:
Mean · Points
Change From Baseline to Week 18 in Pruritus as Measured by ItchRO (Obs)
PointsOpen-label Period: MRX BaselineOpen-label Period: MRX Week 18
Change From Baseline to Week 18 in Pruritus as Measured by ItchRO (Obs)2.909 ± 0.54801.203 ± 0.8446
Statistical analysis
  • Open-label Period: MRX Baseline vs Open-label Period: MRX Week 18 · Student's t-test · p = < 0.0001 · Mean difference (net): -1.704 · 95% CI -2.051 to -1.357
SecondaryChange From Baseline to Week 18 in Pruritus as Measured by ItchRO (Pt)

This secondary efficacy endpoint is the change from baseline to Week 18 in pruritus as measured by ItchRO(Pt) weekly average morning score

Time frame:
Baseline to Week 18
Reported as:
Mean · Points
Change From Baseline to Week 18 in Pruritus as Measured by ItchRO (Pt)
PointsOpen-label Period: MRX BaselineOpen-label Period: MRX Week 18
Change From Baseline to Week 18 in Pruritus as Measured by ItchRO (Pt)2.903 ± 0.66160.831 ± 0.8122
Statistical analysis
  • Open-label Period: MRX Baseline vs Open-label Period: MRX Week 18 · Student's t-test · p = < 0.0001 · Mean difference (net): -2.072 · 95% CI -2.645 to -1.498
SecondaryChange From Week 18 to Week 22 in Pruritus as Measured by ItchRO(Obs)

This secondary efficacy endpoint is the change from Week 18 to Week 22 in pruritus as measured by ItchRO(Obs) weekly average morning score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe).

Time frame:
Week 18 to Week 22
Reported as:
Least squares mean · Points
Change From Week 18 to Week 22 in Pruritus as Measured by ItchRO(Obs)
PointsRandomized Withdrawal Period: MRXRandomized Withdrawal Period: Placebo
Change From Week 18 to Week 22 in Pruritus as Measured by ItchRO(Obs)0.217 ± 0.23451.700 ± 0.2031
Statistical analysis
  • Randomized Withdrawal Period: MRX vs Randomized Withdrawal Period: Placebo · ANCOVA · p = < 0.0001 · Mean difference (net): -1.483 · 95% CI -2.122 to -0.844
SecondaryChange From Week 18 to Week 22 in Pruritus as Measured by ItchRO(Pt)

This secondary efficacy endpoint is the change from Week 18 to Week 22 in pruritus as measured by ItchRO(Pt) weekly average morning score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe).

Time frame:
Week 18 to Week 22
Reported as:
Least squares mean · Points
Change From Week 18 to Week 22 in Pruritus as Measured by ItchRO(Pt)
PointsRandomized Withdrawal Period: MRXRandomized Withdrawal Period: Placebo
Change From Week 18 to Week 22 in Pruritus as Measured by ItchRO(Pt)-0.149 ± 0.37191.839 ± 0.2771
Statistical analysis
  • Randomized Withdrawal Period: MRX vs Randomized Withdrawal Period: Placebo · ANCOVA · p = 0.0013 · Mean difference (net): -1.988 · 95% CI -3.009 to -0.967
SecondaryChange From Baseline to Week 18 in Alkaline Phosphatase

This secondary efficacy endpoint is the mean change from baseline to Week 18 in ALP

Time frame:
Baseline to Week 18
Reported as:
Mean · U/L
Change From Baseline to Week 18 in Alkaline Phosphatase
U/LOpen-label Period: MRX BaselineOpen-label Period: MRX Week 18
Change From Baseline to Week 18 in Alkaline Phosphatase601.3 ± 274.77580.8 ± 215.50
Statistical analysis
  • Open-label Period: MRX Baseline vs Open-label Period: MRX Week 18 · Student's t-test · p = 0.2163 (Data for this analysis were obtained from 31 participants at baseline; 29 of those participants contributed Week 18 data.) · Mean difference (net): -27.8 · 95% CI -72.8 to 17.2
SecondaryChange From Week 18 to Week 22 in Alkaline Phosphatase

This secondary efficacy endpoint is the mean change from Week 18 to Week 22 in ALP

Time frame:
Week 18 to Week 22
Reported as:
Least squares mean · U/L
Change From Week 18 to Week 22 in Alkaline Phosphatase
U/LRandomized Withdrawal Period: MRXRandomized Withdrawal Period: Placebo
Change From Week 18 to Week 22 in Alkaline Phosphatase2.8 ± 22.55-7.2 ± 20.31
Statistical analysis
  • Randomized Withdrawal Period: MRX vs Randomized Withdrawal Period: Placebo · ANCOVA · p = 0.7455 · Mean difference (net): 10 · 95% CI -52.6 to 72.6
SecondaryChange From Baseline to Week 18 in Alanine Aminotransferase

This secondary efficacy endpoint is the mean change from baseline to Week 18 in ALT

Time frame:
Baseline to Week 18
Reported as:
Mean · U/L
Change From Baseline to Week 18 in Alanine Aminotransferase
U/LOpen-label Period: MRX BaselineOpen-label Period: MRX Week 18
Change From Baseline to Week 18 in Alanine Aminotransferase181.0 ± 108.56177.4 ± 92.08
Statistical analysis
  • Open-label Period: MRX Baseline vs Open-label Period: MRX Week 18 · Student's t-test · p = 0.9358 (Data for this analysis were obtained from 31 participants at baseline; 29 of those participants contributed Week 18 data.) · Mean difference (net): -1.3 · 95% CI -33.4 to 30.9
SecondaryChange From Week 18 to Week 22 in Alanine Aminotransferase

This secondary efficacy endpoint is the mean change from Week 18 to Week 22 in alanine aminotransferase (ALT)

Time frame:
Week 18 to Week 22
Reported as:
Least squares mean · U/L
Change From Week 18 to Week 22 in Alanine Aminotransferase
U/LRandomized Withdrawal Period: MRXRandomized Withdrawal Period: Placebo
Change From Week 18 to Week 22 in Alanine Aminotransferase34.5 ± 14.0419.4 ± 12.56
Statistical analysis
  • Randomized Withdrawal Period: MRX vs Randomized Withdrawal Period: Placebo · ANCOVA · p = 0.4472 · Mean difference (net): 15.1 · 95% CI -25.1 to 55.2
SecondaryChange From Baseline to Week 18 in Total Bilirubin

This secondary efficacy endpoint is the mean change from baseline to Week 18 in total bilirubin

Time frame:
Baseline to Week 18
Reported as:
Mean · mg/dL
Change From Baseline to Week 18 in Total Bilirubin
mg/dLOpen-label Period: MRX BaselineOpen-label Period: MRX Week 18
Change From Baseline to Week 18 in Total Bilirubin6.09 ± 5.7815.12 ± 5.337
Statistical analysis
  • Open-label Period: MRX Baseline vs Open-label Period: MRX Week 18 · Student's t-test · p = 0.0893 · Mean difference (net): -0.47 · 95% CI -1.01 to 0.08
SecondaryChange From Week 18 to Week 22 in Total Bilirubin

This secondary efficacy endpoint is the mean change from Week 18 to Week 22 in total bilirubin

Time frame:
Week 18 to Week 22
Reported as:
Least squares mean · mg/dL
Change From Week 18 to Week 22 in Total Bilirubin
mg/dLRandomized Withdrawal Period: MRXRandomized Withdrawal Period: Placebo
Change From Week 18 to Week 22 in Total Bilirubin0.32 ± 0.2650.46 ± 0.238
Statistical analysis
  • Randomized Withdrawal Period: MRX vs Randomized Withdrawal Period: Placebo · ANCOVA · p = 0.7 · Mean difference (net): -0.14 · 95% CI -0.88 to 0.6
SecondaryChange From Baseline to Week 18 in Direct Bilirubin

This secondary efficacy endpoint is the mean change from baseline to Week 18 in direct bilirubin

Time frame:
Baseline to Week 18
Reported as:
Mean · mg/dL
Change From Baseline to Week 18 in Direct Bilirubin
mg/dLOpen-label Period: MRX BaselineOpen-label Period: MRX Week 18
Change From Baseline to Week 18 in Direct Bilirubin4.57 ± 3.6663.98 ± 3.369
Statistical analysis
  • Open-label Period: MRX Baseline vs Open-label Period: MRX Week 18 · Student's t-test · p = 0.0139 · Mean difference (net): -0.5 · 95% CI -0.9 to -0.11
SecondaryChange From Week 18 to Week 22 in Direct Bilirubin

This secondary efficacy endpoint is the mean change from Week 18 to Week 22 in direct bilirubin

Time frame:
Week 18 to Week 22
Reported as:
Least squares mean · mg/dL
Change From Week 18 to Week 22 in Direct Bilirubin
mg/dLRandomized Withdrawal Period: MRXRandomized Withdrawal Period: Placebo
Change From Week 18 to Week 22 in Direct Bilirubin0.13 ± 0.1950.14 ± 0.174
Statistical analysis
  • Randomized Withdrawal Period: MRX vs Randomized Withdrawal Period: Placebo · ANCOVA · p = 0.9517 · Mean difference (net): -0.02 · 95% CI -0.56 to 0.53

Adverse events

Collected over Baseline to study completion (median of 2 years). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open-label Period: Maralixibat (LUM001)0/31 (0%)4/31 (12.9%)29/31 (93.5%)
Randomized Withdrawal Period: MRX0/13 (0%)1/13 (7.7%)7/13 (53.8%)
Randomized Withdrawal Period: Placebo0/16 (0%)1/16 (6.3%)12/16 (75%)
After Randomized Withdrawal Period: Maralixibat0/29 (0%)5/29 (17.2%)25/29 (86.2%)
Long-term Extension Period: Maralixibat0/23 (0%)6/23 (26.1%)23/23 (100%)
Safety Population0/31 (0%)13/31 (41.9%)31/31 (100%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventOpen-label Period: Maralixibat (LUM001)Randomized Withdrawal Period: MRXRandomized Withdrawal Period: PlaceboAfter Randomized Withdrawal Period: MaralixibatLong-term Extension Period: MaralixibatSafety Population
Viral infectionInfections and infestations0/311/130/160/290/231/31
PyrexiaGeneral disorders0/310/131/160/291/232/31
Shock haemorrhagicVascular disorders0/310/131/160/290/231/31
Multiple injuriesInjury, poisoning and procedural complications0/310/131/160/290/231/31
Splenic ruptureInjury, poisoning and procedural complications0/310/131/160/290/231/31
Chest painGeneral disorders0/310/131/160/290/231/31
Forearm fractureInjury, poisoning and procedural complications0/310/130/160/291/231/31
Toxicity to various agentsInjury, poisoning and procedural complications0/310/130/161/291/231/31
Marrow hyperplasiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/310/130/160/291/231/31
Cardiac dysfunctionCardiac disorders0/310/130/160/291/231/31
Most frequent other events
Showing 10 of 144
Most frequent other events
EventOpen-label Period: Maralixibat (LUM001)Randomized Withdrawal Period: MRXRandomized Withdrawal Period: PlaceboAfter Randomized Withdrawal Period: MaralixibatLong-term Extension Period: MaralixibatSafety Population
Abdominal painGastrointestinal disorders12/311/131/166/2912/2318/31
DiarrhoeaGastrointestinal disorders13/311/131/165/297/2318/31
PyrexiaGeneral disorders6/310/131/167/2910/2317/31
VomitingGastrointestinal disorders11/311/131/162/298/2316/31
CoughRespiratory, thoracic and mediastinal disorders3/310/130/163/298/2313/31
NasopharyngitisInfections and infestations4/311/131/168/299/2313/31
PruritusSkin and subcutaneous tissue disorders3/311/135/162/290/239/31
HeadacheNervous system disorders5/310/130/162/294/239/31
Upper respiratory tract infectionInfections and infestations6/312/130/163/294/239/31
Ear infectionInfections and infestations3/310/130/164/295/238/31

Baseline characteristics

Age, Continuous
Age, Continuous(years of age)Open-label Period: Maralixibat
Mean5.4 ± 4.25
Age, Customized
Age, Customized(Participants)Open-label Period: Maralixibat
<2 years6
2 to 4 years9
5 to 8 years9
9 to 12 years4
13 to 18 years3
Sex: Female, Male
Sex: Female, Male(Participants)Open-label Period: Maralixibat
Female12
Male19
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Open-label Period: Maralixibat
American Indian or Alaska NativeNA
AsianNA
Native Hawaiian or Other Pacific IslanderNA
Black or African AmericanNA
WhiteNA
More than one raceNA
Unknown or Not ReportedNA
Region of Enrollment
Region of Enrollment(participants)Open-label Period: Maralixibat
Australia9
Belgium5
France9
Poland3
Spain2
United Kingdom3
08

Study locations

9 sites
  • Children's Hospital Westmead
    Westmead, New South Wales 2145, Australia
  • The Royal Children's Hospital Melbourne
    Parkville, Victoria 3052, Australia
  • Cliniques Universitaires Saint-Luc
    Brussels, Belgium
  • Hopital Femme Mere Enfant De Lyon
    Bron, 69677, France
  • Hopital Necker-Enfants Malades
    Paris, 75015, France
  • Hopital Kremlin Bicetre
    Paris, 94275, France
  • The Children's Memorial Health Institute
    Warsaw, 04-730, Poland
  • Hospital Universitario La Paz- Hospital Materno Infantil
    Madrid, 261, Spain
  • Paediatric Liver Center, Kings College Hospital
    London, SE5 9RS, United Kingdom
09

References and documents

Publications

  • Kamath BM, Goldstein A, Howard R, Garner W, Vig P, Marden JR, Billmyer E, Anderson A, Kirson N, Jacquemin E, Gonzales E. Maralixibat Treatment Response in Alagille Syndrome is Associated with Improved Health-Related Quality of Life. J Pediatr. 2023 Jan;252:68-75.e5. doi: 10.1016/j.jpeds.2022.09.001. Epub 2022 Sep 10. PubMed 36096175 ↗
  • Gonzales E, Hardikar W, Stormon M, Baker A, Hierro L, Gliwicz D, Lacaille F, Lachaux A, Sturm E, Setchell KDR, Kennedy C, Dorenbaum A, Steinmetz J, Desai NK, Wardle AJ, Garner W, Vig P, Jaecklin T, Sokal EM, Jacquemin E. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study. Lancet. 2021 Oct 30;398(10311):1581-1592. doi: 10.1016/S0140-6736(21)01256-3. Epub 2021 Oct 28. PubMed 34755627 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2014 to primary completion in May 2020, 67 months.

Results were first posted in Jul 2021, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2014
First posted
Jun 11, 2014
StartActual
Oct 28, 2014
Primary completionActual
May 28, 2020
CompletionActual
May 28, 2020
Results first posted
Jul 14, 2021
Last update
Jul 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02160782
Responsible party
Sponsor
First posted
Jun 11, 2014
Start date
Oct 28, 2014
Primary completion
May 28, 2020
Completion
May 28, 2020
Results posted
Jul 14, 2021
Last update
Jul 14, 2021

Study contacts

Study Director
study director · Mirum

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maralixibat

Start the discussion